• About
  • Keywords

Toxoplasma gondii & Human Phenotype

Compendium of Known Effects and Ongoing Research

phenothiazines

Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii

October 30, 2003
Jones-Brando, L., Torrey, E.F., Yolken ,R.
Schizophrenia Research 2003; 62: 237-244
Click for abstract
The exact mechanisms of action of some antipsychotics and mood stabilizers have not been elucidated. Response to these medications can vary among individuals. Recent studies indicate that infection with the parasite Toxoplasma gondii may contribute to the symptoms of schizophrenia in some individuals. We investigated commonly used antipsychotic and mood stabilizing medications for their ability to inhibit the replication of this organism. We employed a system for testing compounds for in vitro activity against T gondii. Human fibroblasts (HFF) were treated with test compounds and then exposed to Toxoplasma that has been genetically modified to express cytoplasmic galactosidase. Inhibition by the drugs was determined by spectrophotometric analysis of colorimetric reactions. We tested 12 neuroleptic compounds and found that of these, the antipsychotic haloperidol and the mood stabilizer valproic acid most effectively inhibit Toxoplasma growth in vitro. Valproic acid inhibited the parasite at a concentration below that found in the cerebrospinal fluid and blood of individuals being treated with this medication and displayed synergistic activity with haloperidol and with trimethoprim, an antibiotic commonly used to treat Toxoplasma infections. Several medications used to treat schizophrenia and bipolar disorder have the ability to inhibit the in vitro replication of T gondii. (C) 2002 Elsevier Science B.V. All rights reserved.

Tagged: antiparasitic, antipsychotics, bipolar disorder, cells, chlorpromazine, first-episode schizophrenia, herpes-simplex-virus, human-immunodeficiency-virus, in-vitro, infection, lithium-chloride, mood stabilizers, Parasite, phenothiazines, Schizophrenia, trypanothione reductase

Mental health

Topics

  • Behavior 105
  • Cognitive functions 64
  • Mental health 439
  • Morphology 6
  • Motor functions 10
  • Personality 36
  • Physical health 134
  • Reproduction 36
  • Reviews 40
  • Sensory functions 3
  • Uncategorized 2

Archives

Recent articles

  • Mortality Patterns of Toxoplasmosis and Its Comorbidities in Tanzania: A 10-Year Retrospective Hospital-Based Survey February 6, 2020
  • The role of latent toxoplasmosis in the aetiopathogenesis of schizophrenia–the risk factor or an indication of a contact with cat? February 6, 2020
  • The Association between Toxoplasma gondii Infection and Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis February 6, 2020

Recent Comments

  • Tulammo primers on Diagnostic problems in psychiatry with regard to acquired toxoplasmosis
  • fort pierce mortgage rates on Diagnostic problems in psychiatry with regard to acquired toxoplasmosis
  • www.formlets.comformsfpN4Ll8AEnDHBAkr on Selected infectious agents and risk of schizophrenia among U.S. military personnel
  • cialis on Puppet master: possible influence of the parasite Toxoplasma gondii on managers and employees
  • roof on Diagnostic problems in psychiatry with regard to acquired toxoplasmosis

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Copyright © 2022 Toxoplasma gondii & Human Phenotype.

ToxoBehavior WordPress Theme by Jelena Braum